Pfizer
PFE
$27.65
-0.47%
Pfizer Inc. is a global pharmaceutical giant that develops, manufactures, and markets a broad portfolio of prescription drugs and vaccines, with top-selling products including the pneumococcal vaccine Prevnar, the anticoagulant Eliquis, and the rare-disease drug Vyndamax. As one of the world's largest drugmakers by revenue, Pfizer competes across therapeutic areas such as oncology, immunology, and cardiology, and is currently navigating a post-COVID landscape where its blockbuster vaccine and antiviral sales have normalized. Investor attention is focused on Pfizer's pipeline, particularly its oral GLP-1 candidate for obesity (berobenatide), which represents a potential growth catalyst, while the company also faces headwinds from patent expirations on key drugs and a high dividend yield that has attracted income investors despite broader concerns about growth sustainability.…
PFE
Pfizer
$27.65
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating: Hold. The consensus recommendation is 'buy' with an average target price of $28.61, implying a modest 0.6% upside from the current price of $28.45. While the stock offers a high dividend yield and low valuation, the risks of dividend unsustainability and pipeline uncertainty temper enthusiasm. The thesis is that PFE is a value play with a potential catalyst in obesity, but investors should wait for clearer evidence of earnings growth and dividend safety.
Sign up to view all
PFE 12-Month Price Forecast
Pfizer's valuation is attractive, but the high payout ratio and earnings volatility create significant risk. The stock is likely to trade in a narrow range unless a major catalyst emerges. I would upgrade to bullish if the payout ratio drops below 100% or if berobenatide shows positive phase 3 data, and downgrade to bearish if the dividend is cut or revenue growth stalls.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $28.61 and implied upside of +3.5% versus the current price.
Average Target
$28.61
0 analysts
Implied Upside
+3.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $36
Analyst target range
Pfizer's balance sheet shows a debt-to-equity ratio of 0.78, which is moderate for a large pharmaceutical company, and a current ratio of 1.16, indicating adequate short-term liquidity. The company generated free cash flow of $2.179 billion in Q1 2026, and $9.484 billion on a trailing twelve-month basis, which is strong and supports its dividend payments. However, the company's cash position is relatively low, with cash at end of period of $1.76 billion in Q1 2026, and it has been using cash for acquisitions and debt repayment, as seen in Q4 2025 when it had net cash from investing of -$6.146 billion. The interest coverage ratio of 6.04 in Q1 2026 suggests that Pfizer can comfortably meet its interest obligations, but the high payout ratio and reliance on debt for financing raise concerns about long-term financial flexibility.
Drowning in data?
Find the real signal!
Bulls vs Bears: PFE Investment Factors
Pfizer presents a classic value-income dichotomy: it offers a high dividend yield, low valuation, and improving revenue trends, but faces significant earnings volatility, a stretched payout ratio, and looming patent cliffs. The bull case rests on the pipeline (especially berobenatide) and margin strength, while the bear case centers on dividend sustainability and growth gaps. Currently, the bearish evidence on financial health is more compelling, but the low valuation and potential catalysts tilt the risk-reward slightly positive. The key tension is whether Pfizer can grow earnings enough to cover its dividend and offset patent losses, which will determine if the stock re-rates upward or continues to languish.
Bullish
- Revenue Growth Resumes: Q1 2026 revenue of $14.451B grew 5.37% YoY, a clear turnaround from the COVID-driven decline. This marks the second consecutive quarter of positive growth, signaling stabilization in the core business.
- Strong Gross and Operating Margins: Gross margin of 67.26% and operating margin of 27.9% in Q1 2026 demonstrate efficient cost management and pricing power. These are robust for a large pharma, supporting profitability as revenue scales.
- Attractive Valuation with Forward PE of 9.8: With a forward PE of 9.83, PFE trades at a significant discount to the broader market and its own historical average. This low multiple provides a margin of safety and upside potential if growth sustains.
- High Dividend Yield of 6.9%: The 6.9% dividend yield is historically high and well above the S&P 500 average, making PFE a compelling income play. This yield is supported by strong free cash flow of $9.48B TTM, though the payout ratio is elevated.
Bearish
- Unsustainable Payout Ratio of 125.8%: The dividend payout ratio of 125.8% indicates PFE is paying out more than it earns, a red flag for dividend sustainability. This could force a cut or reduce financial flexibility if earnings don't improve.
- Earnings Volatility and Recent Loss: Q4 2025 posted a net loss of -$1.648B, and TTM EPS is just $0.05, reflecting significant earnings instability. This volatility complicates valuation and increases risk for investors seeking predictable returns.
- Patent Cliff Risks: Key drugs like Eliquis and Prevnar face patent expirations later this decade, threatening revenue. The market is concerned about the lack of blockbuster replacements, as highlighted by recent news on Pfizer's patent cliff risks.
- High Debt and Low Cash Position: With a debt-to-equity ratio of 0.78 and cash of only $1.76B, PFE has limited liquidity buffer. The company relies on debt for acquisitions and dividends, increasing financial risk if cash flows weaken.
PFE Technical Analysis
Pfizer's stock has been in a broad recovery trend over the past year, with a 1-year price change of +15.93%, though this masks significant volatility. The current price of $28.45 sits near the upper end of its 52-week range, at approximately 93% of the distance from the low of $23.58 to the high of $29.21. This positioning near the highs suggests renewed bullish momentum, but also implies the stock may be approaching resistance levels where profit-taking could occur. The stock's beta of 0.299 indicates it is significantly less volatile than the broader market, making it a defensive holding, yet its 52-week range shows it has experienced a drawdown of -17.09% at some point, highlighting that even low-beta stocks can face sharp corrections.
Beta
0.30
0.30x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$24-$29
Price range past year
Annual Return
+12.5%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | -1.6% |
| 3m | +5.5% | +2.2% |
| 6m | +4.0% | +14.4% |
| 1y | +12.5% | +16.2% |
| ytd | +9.8% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory has been uneven but recently turned positive, with the most recent quarter (Q1 2026) reporting revenue of $14.451 billion, a 5.37% year-over-year increase. This marks a recovery from the prior quarter (Q4 2025) which saw revenue of $17.557 billion but a net loss of -$1.648 billion, and from Q1 2025's revenue of $13.715 billion. The growth is driven by the Biopharma segment, which contributed $14.161 billion in Q1 2026, while the corporate nonsegment added $289 million. However, the multi-quarter trend shows volatility, with revenue ranging from $13.283 billion in Q2 2024 to $17.763 billion in Q4 2024, indicating that Pfizer's top line is still stabilizing after the COVID product decline, and the recent growth is a positive sign but not yet a sustained acceleration.
Quarterly Revenue
$14.5B
2026-03
Revenue YoY Growth
+5.4%
YoY Comparison
Gross Margin
67.3%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Pfizer's profitability has been inconsistent, with a net income of $2.688 billion in Q1 2026 (net margin of 18.6%), but a net loss of -$1.648 billion in Q4 2025. The gross margin for Q1 2026 was 67.26%, which is strong for the pharmaceutical industry, and the operating margin was 27.9%, indicating efficient cost management. However, the trailing twelve-month net income is positive, but the company's EPS of $0.47 for Q1 2026 is modest, and the payout ratio of 125.75% suggests that Pfizer is paying out more in dividends than it earns, which is unsustainable in the long term. The company's ROE is 8.99%, and ROA is 5.78%, reflecting moderate returns on equity and assets, but the negative net income in Q4 2025 highlights the earnings volatility that investors must consider.
PE
18.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are prominent: the payout ratio of 125.8% means dividends exceed net income, a situation that is unsustainable without earnings growth or debt. The company's cash position is thin at $1.76B, while debt-to-equity stands at 0.78, and interest coverage of 6.04 provides some cushion but limits flexibility. Earnings have been volatile, with a net loss in Q4 2025 and TTM EPS of just $0.05, making the stock sensitive to any operational hiccup. Free cash flow of $9.48B TTM is a positive, but it is not enough to cover the dividend and debt obligations comfortably in the long run.
FAQ
The primary risks are: 1) Dividend sustainability, as the payout ratio is 125.8%, meaning dividends exceed earnings. 2) Patent expirations on key drugs like Eliquis and Prevnar, which could erode revenue. 3) Pipeline risk, particularly the failure of berobenatide in phase 3 trials. 4) High debt levels with a debt-to-equity ratio of 0.78 and low cash of $1.76B. The most severe risk is a dividend cut, which could lead to a significant sell-off.
The 12-month forecast is mixed: the bull case (25% probability) targets $30-$35, driven by positive pipeline news. The base case (50% probability) targets $27-$30, with modest growth and stable dividend. The bear case (25% probability) targets $23-$26, if the dividend is cut or pipeline fails. The most likely scenario is the base case, with the stock trading near the analyst average target of $28.61. Key assumptions include stable revenue growth and no major negative surprises.
PFE trades at a forward PE of 9.83, which is below the market average and its own historical average, suggesting it is undervalued. The price-to-sales ratio of 2.26 and EV-to-EBITDA of 13.76 are also reasonable for a large pharma. However, the low valuation reflects the market's concerns about earnings sustainability and growth. If the company can maintain its dividend and grow revenue, the stock is likely undervalued; otherwise, the discount is justified.
PFE offers a high dividend yield of 6.9% and a low forward PE of 9.83, but the payout ratio of 125.8% is a red flag. Analyst consensus is 'buy' with an average target of $28.61, implying only 0.6% upside. The stock is a good buy for income investors who can tolerate the risk of a dividend cut, but growth investors may find better opportunities elsewhere. A safer entry point would be below $26, where the yield is higher and downside is more limited.
PFE is more suitable for long-term investment due to its low beta of 0.299, high dividend yield, and potential pipeline catalysts. Short-term trading is possible, but the stock's low volatility and lack of near-term catalysts make it less attractive for traders. A minimum holding period of 3-5 years is recommended to ride out patent cliffs and benefit from pipeline developments. Income investors should focus on the dividend yield, but must monitor the payout ratio for sustainability.
